Drug-Drug Interaction Study: ASP2151 and Montelukast
Status:
Completed
Trial end date:
2015-04-01
Target enrollment:
Participant gender:
Summary
CYP2C8 is involved in the metabolism of many drugs. So, it is important to assess in vivo the
inhibitory effect of ASP2151 on that enzyme to determine any possible drug interactions. The
aim of this trial is to investigate the potential for interaction of ASP2151 with the CYP2C8
probe substrate montelukast.